Close menu




October 1st, 2026 | 07:35 CEST

thyssenkrupp, Strategic Resources, Salzgitter – Steel Stocks That Could Benefit from the Industry's Transformation

  • VTM
  • ironore
  • GreenSteel
  • Investments
Photo credits: Pixabay

Europe's steel industry is currently transforming. Since July 1, the EU has been protecting its steel market with a duty-free quota of 18.345 million metric tonnes and a 50% tariff on all imports exceeding that amount. Starting October 1, importers must also provide proof of where they smelted and cast their steel. This gives manufacturers breathing room to replace blast furnaces with direct reduction plants. However, these plants require high-grade iron ore of the appropriate quality. For those who view steel, raw materials, and restructuring as a unified whole, the new situation could work in their favour. We are therefore taking a closer look at thyssenkrupp, Strategic Resources and Salzgitter.

time to read: 4 minutes | Author: Armin Schulz
ISIN: STRATEGIC RES INC. | CA86277X4093 | TSXV: SR , THYSSENKRUPP AG O.N. | DE0007500001 , SALZGITTER AG O.N. | DE0006202005

Table of contents:


    thyssenkrupp: EUR 1.2 billion EBITDA target for the steel division

    On September 28, thyssenkrupp Steel held its Capital Market Day. In the medium term, the division is aiming for an adjusted EBITDA of at least EUR 1.2 billion, with a margin of at least 11% and positive free cash flow. More than EUR 800 million is expected to come from internal measures. According to the company, the trade defence measures in effect since July cover more than 80% of the European flat steel market. This could give the Duisburg-based company some breathing room. In addition, the division continues to strive for independence, though the Essen-based parent company could retain a minority stake.

    Developments in recent months support these goals. On August 13, thyssenkrupp presented its figures for the third quarter of fiscal year 2025/26. Revenue rose to EUR 8.8 billion, up from EUR 8.2 billion in the prior year. Adjusted EBIT came in at EUR 183 million, compared to EUR 155 million in the same quarter of the previous year. The restructuring and the APEX program appear to be giving the group a boost. The forecast for adjusted EBIT is now EUR 600 to 900 million, up from the previous range of EUR 500 to 900 million.

    The restructuring continues in parallel. Of the planned 11,000 job cuts, the Group has already implemented about 4,000, and it has sold its stake in Hüttenwerke Krupp Mannesmann to Salzgitter. Hot Strip Mill 4 in Duisburg has resumed trial operations following fire damage, and the direct reduction plant for more climate-friendly steel is under construction. If the ramp-up is successful, the division could benefit particularly from tariff protection. Then Duisburg would no longer have to count every euro twice. Until then, the restructuring plan remains the framework. The journey is not yet over.

    Strategic Resources: Pellet Plant for the Steel Transition in Québec

    Replacing blast furnaces with direct reduction plants requires pellets of the appropriate quality. That is exactly what Strategic Resources is working on. A pellet plant with an annual capacity of 4 million metric tonnes is to be built at the deep-water port of Port Saguenay in Québec. A permit has already been granted for the BlackRock project, which currently covers 1.5 million metric tonnes per year. On May 26, Strategic Resources submitted all responses to the questions raised by the Québec Ministry of the Environment regarding the application for the larger facility. The company expects a positive decision in the coming months. A long-term lease agreement for the industrial site is in place.

    Things are also moving forward in Finland. On June 29, the company announced that its magnetite concentrate from the Mustavaara project had been selected for FutSteel. The research project at the University of Oulu has a budget of EUR 17 million and will run from 2026 through 2029, in collaboration with, among others, the steel manufacturer SSAB. The material is being tested as part of a program for hydrogen-based iron production. Strategic Resources views this as confirmation of the material's quality. Additionally, on April 27, the company signed a memorandum of understanding with Tyfast Energy to evaluate battery-grade vanadium oxide derived from Canadian ore. In this way, the company is actively engaging in two future markets at once.

    Key financing details are already in place. According to the company, construction costs for the pellet plant are estimated at USD 470 million, with two-thirds to be financed through debt and one-third through equity. Société Générale is on board as the lead bank, and Orion Mine Finance, an experienced investor, is among the shareholders. A benefit-sharing agreement is in place with the Cree Nation Government for the project's full duration, along with development agreements with three Innu communities. If the financing is finalized, construction could really gain momentum. Construction is then scheduled to begin in 2027.

    Watch YouTube video

    Salzgitter: Aurubis and Cost-Cutting Program Turn Around Earnings

    On August 11, Salzgitter reported its first-half 2026 results. EBITDA VX rose to EUR 459.0 million; in the same period last year, the figure was just EUR 116.8 million. Earnings per share came in at EUR 0.74, following a loss of EUR 1.68 in the first half of 2025. For the full fiscal year 2026, the Executive Board expects revenue of approximately EUR 10.0 billion, EBITDA VX of EUR 725 to 825 million, and profit before taxes VX of EUR 325 to 425 million.

    The jump in profits was largely driven by the investment in Aurubis, which contributed EUR 193.0 million to earnings. Added to this were EUR 97 million in additional savings from the P28 efficiency program, as well as improved performance in the steel, trading, and technology segments. The cost-cutting program has given earnings a boost. While the Lower Saxony-based company remains heavily reliant on a single investment, its core operations have also improved compared to the previous year. The company itself notes that its forecasts are subject to uncertainty, partly due to geopolitical uncertainties.

    Strategically, there have also been significant developments. Salzgitter has fully acquired Hüttenwerke Krupp Mannesmann in Duisburg, and according to the company, the acquisition is expected to contribute a mid-double-digit million amount to adjusted earnings. The Group has divested Klöckner DESMA's elastomer technology business. The Group's net financial debt stood at EUR 792 million as of June 30 and remained stable despite high investments in the SALCOS decarbonization project. If the restructuring of steel production is successful, Salzgitter could benefit from tariff protection, which limits imports from third countries.


    The restructuring of the European steel industry is in full swing. thyssenkrupp has set clear medium-term goals for its steel division and is gaining ground operationally. Strategic Resources is working on the pellet plant in Port Saguenay and has found a research partner in FutSteel for its Finnish ore concentrate. Salzgitter is back in the black and has acquired a new site in Duisburg with Hüttenwerke Krupp Mannesmann. Each of the three companies contributes a building block to the steel industry's transformation, from raw materials to finished sheet metal, and the EU's tariff protection provides backing for the restructuring. All three are working toward the same goal.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read